GlassScriptPhysician profile
Shahabuddin Khan
NPI 1639134828
$4,374.19
in general payments reported to CMS, 2019-2025
36 companies · $727 in 2025
The $727 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $476 · 2021: $676 · 2022: $558 · 2023: $613 · 2024: $553 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,892.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,260.90 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $406.95 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $372.98 | 2019-2025 | Lifevest |
| Amgen INC. | $331.89 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.83 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $285.10 | 2022-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $120.04 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $118.24 | 2019-2025 | Camzyos |
| Bridgebio Pharma, INC. | $114.70 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $99.70 | 2020-2021 | |
| Boston Scientific Corporation | $84.13 | 2019-2024 | Watchman Flx |
| Chiesi USA, INC. | $83.64 | 2022 | |
| Daiichi Sankyo INC. | $79.10 | 2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $76.74 | 2023-2024 | Inpefa |
| Abbott Laboratories | $66.21 | 2023-2025 | Diamondback Peripheral, Xience Skypoint, Xact |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.57 | 2022-2023 | |
| Impulse Dynamics (USA) INC. | $52.38 | 2022 | |
| Esperion Therapeutics, INC. | $43.03 | 2020-2025 | Nexletol |
| Cardiovascular Systems INC. | $41.81 | 2021 | |
| Biotronik INC. | $36.91 | 2020-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $35.92 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $32.85 | 2021-2023 | |
| Novo Nordisk INC | $30.28 | 2021-2022 | |
| Philips North America LLC | $29.77 | 2023 | |
| Alnylam Pharmaceuticals INC. | $25.41 | 2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $21.71 | 2025 | Evkeeza |
| Cardiva Medical, INC. | $21.44 | 2024 | Optowire |
| Teleflex LLC | $19.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.85 | 2025 | |
| Astellas Pharma US INC | $18.56 | 2022 | |
| Corcept Therapeutics | $15.97 | 2022 | |
| Tactile Systems Technology INC | $15.80 | 2023 | Flexitouch Plus, Entre Plus |
| Koya Medical, INC. | $15.74 | 2025 | Dayspring, Koya Medical |
| Kiniksa Pharmaceuticals, LTD. | $15.14 | 2023 | Arcalyst |
| Medtronic Vascular, INC. | $12.21 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahabuddin Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.